Affimed NV AFMD.OQ, AFMD.O is expected to show a rise in quarterly revenue when it reports results on March 24 (estimated) for the period ending December 31 2024
The Heidelberg Baden-wuerttemberg-based company is expected to report a 178.7% increase in revenue to €1.151 million from €413 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Affimed NV is for a loss of 81 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Affimed NV is $11.00, above its last closing price of $0.90.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.92 | -0.94 | -0.94 | Met | -0.2 |
Jun. 30 2024 | -1.02 | -0.89 | -1.01 | Missed | -13.1 |
Mar. 31 2024 | -1.53 | -1.43 | -1.27 | Beat | 11.3 |
Dec. 31 2023 | -1.10 | -1.54 | -1.35 | Beat | 12.5 |
Sep. 30 2023 | -1.83 | -1.84 | -1.60 | Beat | 13.1 |
Jun. 30 2023 | -1.90 | -1.90 | -2.00 | Missed | -5.5 |
Mar. 31 2023 | -1.96 | -1.95 | -2.10 | Missed | -7.4 |
Dec. 31 2022 | -1.94 | -1.94 | -2.20 | Missed | -13.2 |
This summary was machine generated March 21 at 12:52 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。